Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medisync Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$15,515,858

1,284 payments

Through program year 2025, Medisync Clinical Research LLC is reported as receiving $15,515,858 in research payments, across 1,284 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,866 4
2024 Research $94,657 12
2023 Research $750,395 105
2022 Research $5,126,152 473
2021 Research $5,406,029 377
2020 Research $3,155,687 169
2019 Research $978,074 144

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $10,248,917 548 payments
  2. Moderna TX, Inc. $3,675,387 281 payments
  3. Sanofi Pasteur Inc. $483,670 142 payments
  4. GlaxoSmithKline, LLC. $343,193 143 payments
  5. BioNTech SE $213,195 29 payments
  6. Seqirus USA Inc $212,181 12 payments
  7. Genentech, Inc. $101,337 17 payments
  8. Sanofi US Services Inc. $100,091 19 payments
  9. AbbVie, Inc. $69,344 36 payments
  10. Esperion Therapeutics, Inc. $27,640 41 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $5,758,263 175 payments
  2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $2,761,781 197 payments
  3. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $1,450,218 91 payments
  4. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $1,020,059 59 payments
  5. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $941,220 66 payments
  6. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $490,378 55 payments
  7. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $423,228 29 payments
  8. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $289,526 44 payments
  9. MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $244,380 59 payments
  10. Bnt162-17 $213,195 29 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record